Page last updated: 2024-11-11

(8R)-7-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6603797
CHEMBL ID19130
CHEBI ID92685
SCHEMBL ID107293

Synonyms (27)

Synonym
BRD-K39187410-001-01-7
r(-)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,10,11-triol
NCGC00015294-01
lopac-d-029
LOPAC0_000445
BPBIO1_001390
BIOMOL-NT_000073
smr000326877
MLS000860019 ,
NCGC00162155-04
CHEMBL19130 ,
(-)6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,10,11-triol
bdbm50010698
(r)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,10,11-triol
NCGC00162155-03
CCG-204537
methyl[?]triol
SCHEMBL107293
bdbm52988
r( )-2,10,11-trihydroxyaporphine hydrobromide
cid_11957531
CHEBI:92685
(6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,10,11-triol
Q27164387
(8r)-7-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2,13,14-triol
SDCCGSBI-0050430.P002
PD006173
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aporphine alkaloidAny benzylisoquinoline alkaloid that has a structure based on 4H-dibenzo[de,g]quinoline or its 3-methyl derivative.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency13.35190.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency13.35190.025120.237639.8107AID886; AID893
dopamine D1 receptorHomo sapiens (human)Potency0.08200.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency6.00760.100020.879379.4328AID488773; AID588453; AID588456
RGS12Homo sapiens (human)Potency25.11890.794310.991425.1189AID879
ClpPBacillus subtilisPotency28.18381.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID493107
NFKB1 protein, partialHomo sapiens (human)Potency8.91250.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency2.23870.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency8.91250.000811.382244.6684AID686978; AID686979
ThrombopoietinHomo sapiens (human)Potency10.00000.02517.304831.6228AID917; AID918
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency2.51190.00137.762544.6684AID914; AID915
hypothetical protein, conservedTrypanosoma bruceiPotency21.33130.223911.245135.4813AID624147
regulator of G-protein signaling 4Homo sapiens (human)Potency0.66950.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.68340.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency58.47890.016525.307841.3999AID602332
D(1A) dopamine receptorHomo sapiens (human)Potency1.71080.02245.944922.3872AID488982; AID488983
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency4.46680.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency1.33710.006026.168889.1251AID488953
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1Homo sapiens (human)Potency25.11890.794312.126325.1189AID879
mitogen-activated protein kinase 1Homo sapiens (human)Potency12.58930.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency3.76860.133725.412989.1251AID488816; AID588795
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency16.83710.00378.618923.2809AID2660; AID2666; AID2667; AID2668
M-phase phosphoprotein 8Homo sapiens (human)Potency29.93490.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency3.99150.00106.000935.4813AID943; AID944
pyruvate kinase PKM isoform bHomo sapiens (human)Potency39.81072.511912.262825.1189AID954; AID958
D(1A) dopamine receptorSus scrofa (pig)Potency14.68920.00378.108123.2809AID2667
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency19.01157.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency9.52830.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)IC50 (µMol)2.20500.00030.50267.7625AID45982; AID45983
DRattus norvegicus (Norway rat)Ki0.80000.00010.610010.0000AID61497
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)2.20500.00030.39075.4000AID45982; AID45983
D(2) dopamine receptorBos taurus (cattle)IC50 (µMol)0.87370.00100.79948.0000AID62451; AID62452; AID62453
D(2) dopamine receptorBos taurus (cattle)Ki0.00220.00000.58366.1000AID62464
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)2.20500.00030.35635.4000AID45982; AID45983
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)2.20500.00030.38715.4000AID45982; AID45983
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)2.20500.00010.54948.4000AID45982; AID45983
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00040.00000.437510.0000AID65113
DBos taurus (cattle)IC50 (µMol)0.87370.00100.47208.0000AID62451; AID62452; AID62453
DBos taurus (cattle)Ki0.00220.00012.367610.0000AID62464
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
synaptic transmission, dopaminergicDBos taurus (cattle)
vasodilationDBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
endoplasmic reticulum membraneDBos taurus (cattle)
dendritic spineDBos taurus (cattle)
ciliary membraneDBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID62453Tested for binding to dopamine receptor using [3H]spiroperidol as radioligand in calf caudate nucleus homogenates.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine.
AID62464Agonistic activity against calf striatal Dopamine receptor using [3H]- ADTN radioligand1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID62451Tested for binding to dopamine receptor using [3H]- ADTN as radioligand in calf caudate nucleus homogenates.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine.
AID45982Inhibition of [3H]apomorphine binding to calf caudate membrane preparation (p4)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
AID34459Dopamine sensitive adenylate cyclase activity (stimulation) in homogenates of rat brain striatal tissue was assessed at 50 uM of compound; ++ = 41-60% incresae of cAMP above basal activity1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
AID45983Inhibition of [3H]spiroperidol binding to calf caudate membrane preparation (p4)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID61497Binding affinity at rat striatal Dopamine receptor D1 using [3H]- SCH-23390 radioligand1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID385420Displacement of [3H]raclopride from dopamine D2 receptor in rat striatal membrane2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines.
AID61058Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as high affinity state1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
2-Haloaporphines as potent dopamine agonists.
AID62452Tested for binding to dopamine receptor using [3H]apomorphine as radioligand in calf caudate nucleus homogenates.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine.
AID226917Ratio of binding affinity of D2 to binding affinity of D11990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID65113Binding affinity at rat striatal Dopamine receptor D2 using [3H]- piperone radioligand1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID34434Ability (250 uM) to stimulate dopamine sensitive adenylate cyclase from rat corpus striatum in the presence of excess ATP1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (17.65)18.7374
1990's1 (5.88)18.2507
2000's3 (17.65)29.6817
2010's5 (29.41)24.3611
2020's5 (29.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.11 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]